AbbVie, AstraZeneca, and Bristol-Myers Squibb Launch AISB Bind AI Initiative
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
AbbVie, AstraZeneca, and Bristol-Myers Squibb launched AISB Bind, a new federated initiative focused on artificial intelligence in drug discovery. The collaboration aims to collaboratively train an AI model that predicts how small molecules bind to their protein targets, guiding early drug discovery steps like virtual screening and lead optimization. This initiative builds on prior work that successfully raised high-quality prediction shares from 36% to 52% using federated training across proprietary structures.
From finanznachrichten.de
Why it matters
The initiative allows the partners to prioritize promising molecules computationally, potentially reducing the number of unsuccessful candidates tested. This shared approach to advanced drug discovery is being established among major industry peers.
Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.
From finanznachrichten.de
Who's involved
- AbbVieFounding partner in the AISB Bind AI initiative, contributing data to guide early drug discovery.
- AstraZenecaFounding partner in the AISB Bind AI initiative, contributing data to guide early drug discovery.
- Bristol-Myers SquibbFounding partner in the AISB Bind AI initiative, contributing data to guide early drug discovery.
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
AstraZeneca
British-Swedish pharmaceutical company
-
Bristol-Myers Squibb
American pharmaceutical company